Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piclidenoson for Active Noninfectious Intermediate or Posterior Uveitis
NCT01905124Phase 2Withdrawn
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Jan 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of piclidenoson in intermediate uveitis (IU), posterior uveitis, sponsored by Can-Fite BioPharma Ltd.. Planned start Jan 2019; status: withdrawn.
02
Drugs
piclidenoson
03
Conditions
intermediate uveitis (IU)posterior uveitis
Beyond the preview
Go deeper on NCT01905124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01905124.